Xenpozyme

Generic name: Olipudase Alfa-rpcp
Dosage form: intravenous (infusion) injection
Drug class: Lysosomal enzymes

Usage of Xenpozyme

Xenpozyme (Olipudase alfa-rpcp) is an enzyme replacement therapy used for the treatment of Acid Sphingomyelinase Deficiency (ASMD). ASMD is a rare, progressive, inherited disease that was previously known as Niemann-Pick disease types A, A/B and B.

ASMD is a type of lysosomal storage disease that is caused by the lack of a properly working enzyme known as acid sphingomyelinase (ASM). The production of this enzyme is controlled by a gene called SMPD1. Changes in the SMPD1 gene in people with ASMD mean that they don't produce enough of the ASM enzyme to break down a fatty substance in their cells called sphingomyelin. This leads to the build up of sphingomyelin, which damages multiple organs including the liver, lungs, spleen and heart. ASMD can also affect the digestive system and blood.

Xenpozyme works by supplying Olipudase alfa-rpcp, which works the SAMe way the natural ASM enzyme does.

When Xenpoyme was approved by the US Food and Drug Administration (FDA) in August 2022, it was the first and only treatment to have been approved for non-central nervous system manifestations of ASMD in adults and children.

Xenpozyme side effects

Serious side effects of Xenpozyme include:

  • See 'Important information' above

    • The most common side effects of Xenpozyme in adult patients (incidence ≥10%) are:

  • Headache
  • Cough
  • Diarrhea
  • Hypotension
  • Ocular hyperemia

    • The most common side effects of Xenpozyme in pediatric patients (incidence ≥20%) are:

  • Pyrexia
  • Cough
  • Diarrhea
  • Rhinitis
  • Abdominal pain
  • Vomiting
  • Headache
  • Urticaria
  • Nausea
  • Rash
  • Arthralgia
  • Pruritus
  • Fatigue
  • Pharyngitis

    • These are not all of the possible side effects of this medication. Call your healthcare professional for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Xenpozyme

    Tell your doctor if you are pregnant or plan to become pregnant. The initiation or escalation of Xenpozyme dosing is not recommended during pregnancy as it may increase risk of defects in the fetus. The decision to continue or discontinue maintenance dosing, if you are a pregnant female, should be determined by you and your doctor and should consider your need for this medication, the potential drug-related risks to the fetus, and the potential risks due to untreated maternal ASMD disease.

    If you are a female of reproductive potential, your doctor will verify your pregnancy status before you start treatment with this medication. You should use effective contraception during Xenpozyme treatment and for 14 days after your last dose if treatment is discontinued.

    Tell your doctor if your are breastfeeding or plan to breastfeed. It is likely that Xenpozyme is found in breastmilk. Talk to your doctor about the best way to feed your baby while receiving this medication.

    Relate drugs

    How to use Xenpozyme

    The recommended adult and pediatric doSages of Xenpozyme for the dose escalation and maintenance phases are based on body weight as follows for patients with a body mass index (BMI):

  • ≤ 30 - the dosage is based on actual body weight (kg)
  • > 30 - the dosage is based on adjusted body weight (kg). Calculate an adjusted body weight (kg) based on height in meters. Adjusted body weight (kg) = (actual height in m)2 x 30

    • Adults

    The recommended adult starting dose of Xenpozyme is 0.1 mg/kg administer as an IV infusion.

    The recommended Xenopzyme dose escalation regimen is listed in the table below.

    Adult Patients 18 years and older Week 0/Day 1 First dose 0.1 mg/kg Week 2 Second dose 0.3 mg/kg Week 4 Third dose 0.3 mg/kg Week 6 Fourth dose 0.6 mg/kg Week 8 Fifth dose 0.6 mg/kg Week 10 Sixth dose 1 mg/kg Week 12 Seventh dose 2 mg/kg Week 14 Eighth dose 3 mg/kg

    The recommended adult maintenance dose of Xenopzyme is 3 mg/kg via IV infusion every 2 weeks.

    Pediatric patients

    The recommended pediatric starting dose of Xenopozyme is 0.03 mg/kg administered as an IV infusion.

    The recommended Xenopzyme dose escalation regimen is listed in the table below.

    Pediatric Patients 0 to 17 years Week 0/Day 1 First dose 0.03 mg/kg Week 2 Second dose 0.1 mg/kg Week 4 Third dose 0.3 mg/kg Week 6 Fourth dose 0.3 mg/kg Week 8 Fifth dose 0.6 mg/kg Week 10 Sixth dose 0.6 mg/kg Week 12 Seventh dose 1 mg/kg Week 14 Eighth dose 2 mg/kg Week 16 Ninth dose 3 mg/kg

    The recommended pediatric maintenance dose of Xenopzyme is 3 mg/kg via IV infusion every 2 weeks.

    Warnings

    Xenpozyme can cause serious side effects including:

    1. Hypersensitivity Reactions Including Anaphylaxis Your doctor may decide to give you antiHistamine, anti-fever, and/or steroid medications before your infusions.

  • If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, your doctor should discontinue Xenpozyme immediately and initiate appropriate medical treatment.
  • If a mild or moderate hypersensitivity reaction occurs, your doctor may adjust or temporarily withhold your infusion rate or dose of this medication. Hypersensitivity reactions, including anaphylaxis, have been reported in olipudase alfa-treated patients.
  • Signs of hypersensitivity reactions in adults included hives, itchy skin, skin redness, rash, swelling underneath the skin, and tender bumps under the skin.
  • Hypersensitivity reactions in pediatric patients included hives, itchy skin, rash, and localized swelling.

    • 2. Infusion-Associated Reactions

    Your doctor may decide to give you antihistamine, anti-fever, and/or steroid medications before your infusions to reduce the risk of infusion-associated reactions (IARs). However, IARs may still occur after receiving these medications.

  • If severe IARs occur, your doctor should discontinue Xenpozyme immediately and initiate appropriate medical treatment.
  • If a mild or moderate IAR occurs, your doctor may adjust or temporarily withhold your infusion rate or dose of this medication.

    • The most frequent IARs in:

  • adult patients were headache, rash, vomiting, and hives;
  • pediatric patients were hives, swelling, headache, nausea, fever, and vomiting.

    • An acute phase reaction (APR), an acute inflammatory response accompanied by elevations in inflammatory protein concentrations from blood tests, was observed.

  • Most of the APRs occurred at 48 hours post infusion during the dose escalation period.
  • The most common symptoms of APRs were fever, vomiting, and diarrhea.
  • Your doctor can manage APRs like other IARs you may experience.

    • 3. Elevated Transaminases Levels

    Xenpozyme may be associated with elevated liver enzymes, known as transaminases, within 24 to 48 hours after infusion.

  • Elevated transaminase levels were reported in patients during the dose escalation phase in clinical trials.

    • To manage the risk of elevated transaminase levels, your doctor should check your liver enzyme levels with a blood test:

  • within one month before starting Xenpozyme;
  • within 72 hours before any infusion during the dose escalation phase, or before your next scheduled infusion if you missed a dose.

    • Based on the levels of transaminases from your blood tests, your doctor may make changes to your dose or infusion schedule.

    Upon reaching the recommended maintenance dose, transaminase testing is recommended to be continued as part of routine clinical management of ASMD.

    4. Risk of Fetal Malformations During Dosage Initiation or Escalation in Pregnancy

    Xenpozyme dosage initiation or escalation, for a female at any time during her pregnancy, is not recommended as it may increase risk of defects in the fetus. The decision to continue or discontinue maintenance dosing, if you are a pregnant female, should be determined by you and your doctor and should consider your need for this medication, the potential drug-related risks to the fetus, and the potential risks due to untreated maternal ASMD disease.

    If you are a female of reproductive potential, your doctor will verify your pregnancy status before you start treatment with Xenpozyme. You should use effective contraception during treatment and for 14 days after your last dose if this medication is discontinued.

    What other drugs will affect Xenpozyme

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords